NEWCaplight raises a $16M Series A, led by BlackRock and Fin Capital →
Skip to main content
Caplight Logo









Adaptilens

Adaptilens

Private
Boston, MassachusettsHealthcare & Life Scienceshttps://adaptilens.com/

Last Round

Series A

Apr 29, 2024

Total Funding Raised

$20.86M

Company Overview

Adaptilens is a medical device company that develops an innovative intraocular lens that mimics the natural human lens, providing patients with clear vision at all distances and reducing their reliance on glasses and contact lenses.

Sector

Healthcare & Life Sciences

Verticals

Medical Devices, Biotechnology, Advanced Materials

Business Model

B2B

Customer Profile

Hardware Sales

AI Layer

Non-AI

Keywords

intraocular lensIOLaccommodating intraocular lensA-IOLcataract surgerybiomimetic lenspresbyopia correctionmedical deviceophthalmologyvision restorationpolymer technologypremium IOLmultifocal IOL alternative

Historical Pricing

Historical view of private secondary pricing and transaction trends.

Unlock Pricing Charts

Sign up to view complete historical pricing and secondary transactions.

Caplight Momentum Score

Proprietary index based on bid/ask volume and sentiment.

View Momentum History

Track how buyer interest and sentiment changes over time.

Adaptilens Comparables

Compare Adaptilens with similar companies based on industry and business-model similarity.

Adaptilens comparables — related companies by embedding similarity
CompanySimilarityMarket Cap
LensGen
90%
JelliSee Ophthalmics Inc.
90%
Atia Vision
89%

Adaptilens Funding Rounds

Historical fundraising activity

Data table
RoundDateAmount RaisedValuationInvestorsSources
Series AApr 29, 2024
GrantMay 5, 2022
GrantJun 14, 2021
SeedNov 12, 2020
SeedAug 5, 2020

Key People

Founding team and executive leadership

Liane Clamen

Founder And CEO

Founding Team

Daniel Stanley

Chief Operating Officer

Executive Team

Adaptilens Investors

Notable investors and investment history

Adaptilens investors
InvestorRounds
Massachusetts Life Sciences CenterGrant
Pillar VCSeries A, Seed
Accanto PartnersSeed, Series A
380 CapSeries A

Market signals

Structured signals derived from secondary market and firmographic data.

  • Nov 12, 2020

    $1.6M round led by Pillar VC

Adaptilens Filings

SEC and related filings with document metadata.

Data table
TypedDateAmount OfferedAmount SoldFillingPagesDownload
Mock Valuation
Sign Up to view
Mock Valuation
Sign Up to view
Mock Valuation
Sign Up to view
Mock Valuation
Mock Valuation
Sign Up to view
Mock Valuation
Sign Up to view
Mock Valuation
Sign Up to view
Mock Valuation
Mock Valuation
Sign Up to view
Mock Valuation
Sign Up to view
Mock Valuation
Sign Up to view
Mock Valuation
Mock Valuation
Sign Up to view
Mock Valuation
Sign Up to view
Mock Valuation
Sign Up to view
Mock Valuation

Adaptilens Filings

SEC and related filings with document metadata.

Frequently Asked Questions

Common questions about Adaptilens's valuation, stock price, and market status.

Firmographic Details

HeadquartersBoston, Massachusetts
Employee Range9
Year Founded2019
Last FundingApr 29, 2024

Institutional Data Access

Join leading institutional investors using Caplight to access private market data, discover pricing, and execute secondary block trades.

Requires verified institutional or accredited status.